Talquetamab-tgvs: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 May 2024

13 May 2024

  • curprev 20:3820:38, 13 May 2024‎ Muhammad Waleed talk contribs‎ 2,766 bytes +2,766‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent..."
Retrieved from "https://www.wikidoc.org/index.php/Talquetamab-tgvs"